ASH 2021 Conference Coverage on VuMedi
ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with MF
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
John Mascarenhas
By
ASH 2021 Conference Coverage on VuMedi
FEATURING
John Mascarenhas
Login to view comments.
Click here to Login